FIELD: pharmaceutics.
SUBSTANCE: present invention relates to a pharmaceutical composition for oral administration containing 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide, its salt or solvate as active pharmaceutical ingredient and fumaric acid as acid additive. Fumaric acid is contained in an amount of 0.25 to 5 weight fractions on the weight ratio of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamid.
EFFECT: also described is method of stabilization, improve solubility and improved intestinal absorption of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide by adding of fumaric acid to pharmaceutical composition.
12 cl, 5 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PIPERAZINE COMPOUND INHIBITING PROSTAGLANDIN-D-SYNTHASE | 2010 |
|
RU2496778C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING SIGMA RECEPTOR LIGANDS | 2010 |
|
RU2549882C2 |
| PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2470637C2 |
| OBTAINING A TETRACYCLIC COMPOUND CONTAINED IN A HIGH DOSE | 2015 |
|
RU2724056C2 |
| OXAZOLIDINONES FOR TREATING AND/OR PREVENTING CARDIAC EMBARRASSMENTS | 2008 |
|
RU2494740C2 |
| PHARMACEUTICAL COMPOSITIONS, INCLUDING NEP INHIBITORS, INHIBITORS OF SYSTEM PRODUCING ENDOGENIC ENDOTHELIUM AND DIURETICS | 2006 |
|
RU2409366C2 |
| PRUCALOPRID N-OXIDE | 2003 |
|
RU2301806C2 |
| PHARMACEUTICAL COMPOSITION | 2012 |
|
RU2630617C2 |
| SOLID PHARMACEUTICAL COMPOSITION FOR MANUFACTURING ORAL ANTIRETROVIRAL THERAPEUTIC AGENT | 2020 |
|
RU2760129C1 |
| COMBINED THERAPY WITH APPLICATION OF CENICRIVIROC FOR FIBROSIS TREATMENT | 2015 |
|
RU2723559C2 |
